Hercules Capital LSE:0J4M Rapporto sulle azioni Dati finanziari dell'azienda + 8 Analisti
Hercules Capital, Inc.
LSE:0J4M Rapporto sulle azioni
Premi Analisi del rischio Vedi tutti gli assegni di rischio Hercules Capital, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Hercules Capital Prezzi storici delle azioni Prezzo attuale dell'azione US$19.94 Massimo di 52 settimane US$21.93 Minimo di 52 settimane US$15.13 Beta 1.34 1Variazione di 1 mese 1.84% Variazione a 3 mesi 9.86% Variazione di 1 anno 26.32% 3Variazione a 3 anni 16.27% Variazione a 5 anni n/a Variazione dall'IPO 52.21%
Notizie e aggiornamenti recenti
Third quarter 2024 earnings released: EPS: US$0.42 (vs US$0.19 in 3Q 2023) Nov 01
Second quarter dividend of US$0.48 announced Oct 30
Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter 2024, Payable on November 20, 2024 Oct 28
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 20
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 17 Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
Vedi altri aggiornamenti
Third quarter 2024 earnings released: EPS: US$0.42 (vs US$0.19 in 3Q 2023) Nov 01
Second quarter dividend of US$0.48 announced Oct 30
Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter 2024, Payable on November 20, 2024 Oct 28
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 20
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 17 Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC). Aug 23
KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC). Aug 22
Second quarter 2024 earnings released: EPS: US$0.26 (vs US$0.66 in 2Q 2023) Aug 04
First quarter dividend of US$0.48 announced Aug 02
Hercules Capital, Inc. Declares Cash Distribution for the Second Quarter 2024, Payable on August 20, 2024 Aug 01
Hercules Capital, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC completed the acquisition of ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others. May 15
First quarter dividend of US$0.48 announced May 06
First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.69 in 1Q 2023) May 03
Hercules Capital, Inc. Declares First Quarter Cash Dividend, Payable on May 14, 2024 Apr 30
Hercules Capital, Inc., Annual General Meeting, Jun 20, 2024 Apr 24
Hercules Capital, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 20
KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million. Apr 04
Upcoming dividend of US$0.48 per share Feb 20
Full year 2023 earnings released: EPS: US$2.34 (vs US$0.80 in FY 2022) Feb 16
Hercules Capital, Inc. Declares Cash Distribution for the Fourth Quarter 2023, Dividend Payable on March 6, 2024 Feb 13
Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC entered into an Agreement and Plan of Merger to acquire ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others for approximately $150 million. Feb 07
Hercules Capital, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 26
Upcoming dividend of US$0.48 per share at 12% yield Nov 07
Third quarter 2023 earnings released: EPS: US$0.19 (vs US$0.41 in 3Q 2022) Nov 03
Hercules Capital, Inc. Declares Total Cash Distribution the Third Quarter 2023, Payable on November 22, 2023 Nov 01
Hercules Capital, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13
New major risk - Revenue and earnings growth Oct 08
Hercules Capital Appoints Nikos Theodosopoulos an Independent Member of its Board of Directors and to Serve on Audit Committee Sep 26
Upcoming dividend of US$0.48 per share at 11% yield Aug 10 Hercules Capital, Inc. has completed a Follow-on Equity Offering. Aug 09
New major risk - Revenue and earnings growth Aug 06
Second quarter 2023 earnings released: EPS: US$0.67 (vs US$0.088 loss in 2Q 2022) Aug 04
Hercules Capital Declares Cash Distribution for the Second Quarter 2023, Payable August 25, 2023 Aug 02
Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 12
Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 11
Independent Director recently bought US$98k worth of stock May 10
First quarter 2023 earnings released: EPS: US$0.70 (vs US$0.033 loss in 1Q 2022) May 06
Investor sentiment deteriorates as stock falls 18% Mar 11
Upcoming dividend of US$0.47 per share at 13% yield Feb 22
Full year 2022 earnings released: EPS: US$0.80 (vs US$1.50 in FY 2021) Feb 20 Hercules Capital Increases Its Quarterly Cash Distribution for the Fourth Quarter of 2022, Payable on March 9, 2023
Hercules Capital, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Hercules Capital, Inc. Announces Resignation of Brad Koenig as Member of the Board Jan 28
Third quarter 2022 earnings released: EPS: US$0.42 (vs US$0.20 in 3Q 2021) Nov 04
Upcoming dividend of US$0.51 per share Nov 02 Sumitovant Biopharma Ltd. signed an agreement to acquire a 47.83% stake in Myovant Sciences Ltd for $1.2 billion. Oct 24
Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders. Oct 22
Hercules Capital, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter of 2022, Payable on November 17, 2022 Oct 19 Sumitovant Biopharma Ltd. entered into a non-binding proposal to acquire Myovant Sciences Ltd. (NYSE:MYOV) for $1.2 billion. Oct 03
Upcoming dividend of US$0.50 per share Aug 01
Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.71 profit in 2Q 2021) Jul 30
Hercules Capital, Inc. Increases Quarterly Cash Distribution for the Second Quarter of 2022, Payable on August 16, 2022 Jul 27
Hercules Capital, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 15
Hercules Capital, Inc. Appoints Deanne Aguirre to its Board of Directors Jun 25
First quarter 2022 earnings released: US$0.028 loss per share (vs US$0.56 profit in 1Q 2021) May 07 Hercules Capital, Inc. Announces Cash Distribution for the First Quarter of 2022, Payable on May 24, 2022
Hercules Capital, Inc., Annual General Meeting, Jun 23, 2022 May 02
Hercules Capital, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 15
Upcoming dividend of US$0.48 per share Mar 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Hercules Capital Declares Cash Distribution for the Fourth Quarter of 2021, Payable on March 16, 2022 Feb 24
Hercules Capital, Inc. to Report Q4, 2021 Results on Feb 22, 2022 Feb 09
Hercules Capital, Inc. Announces Executive Changes Feb 02
High number of new directors Dec 02
Upcoming dividend of US$0.40 per share Nov 02
Third quarter 2021 earnings released: EPS US$0.20 (vs US$0.38 in 3Q 2020) Oct 30
Chief Compliance Officer, General Counsel & Secretary Melanie Grace has left the company Oct 03
Chief Compliance Officer, General Counsel & Secretary Melanie Grace has left the company Sep 29
Upcoming dividend of US$0.39 per share Aug 03
Second quarter 2021 earnings released: EPS US$0.71 (vs US$0.55 in 2Q 2020) Aug 03
Independent Director Carol Foster has left the company Jul 15
Thoma Bravo, LLC reached an agreement to acquire Greenphire, Inc. from The Riverside Company, Hercules Capital, Inc. (NYSE:HTGC) and Ares Capital Management LLC. May 27
Key Executive recently sold US$350k worth of stock May 06
Hercules Capital, Inc. Announces Dividend for the Year 2021 May 01
First quarter 2021 earnings released: EPS US$0.56 (vs US$0.27 loss in 1Q 2020) May 01 Hercules Capital Announces Supplemental Cash Distribution for the First Quarter of 2021, Payable on May 19, 2021
Hercules Capital, Inc. announced that it has received $100 million in funding Mar 06
Full year 2020 earnings released: EPS US$2.02 (vs US$1.71 in FY 2019) Feb 25
Revenue beats expectations Feb 25
BridgeBio Pharma, Inc. (NasdaqGS:BBIO) completed the acquisition of remaining 36.3% stake in Eidos Therapeutics, Inc. (NasdaqGS:EIDX). Jan 28
Independent Director recently bought US$50k worth of stock Nov 24
Independent Director recently bought US$50k worth of stock Nov 20 Rendimenti per gli azionisti 0J4M GB Capital Markets GB Mercato 7D 4.1% 1.9% -0.8% 1Y 26.3% 30.6% 7.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 0J4M ha avuto una performance inferiore rispetto al UK Capital Markets che ha registrato un rendimento 30.6 % nell'ultimo anno.
Rendimento vs Mercato: 0J4M ha superato il mercato UK che ha restituito 7.9 % nell'ultimo anno.
Volatilità dei prezzi Is 0J4M's price volatile compared to industry and market? 0J4M volatility 0J4M Average Weekly Movement 2.9% Capital Markets Industry Average Movement 3.5% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.0% 10% least volatile stocks in GB Market 2.6%
Prezzo delle azioni stabile: 0J4M non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 3% ) di 0J4M è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2003 100 Scott Bluestein www.htgc.com
Hercules Capital, Inc. è una società di sviluppo aziendale. L'azienda è specializzata nella fornitura di private equity, debito di rischio e capitale di crescita a società private sostenute da capitale di rischio in tutte le fasi di sviluppo, dalla fase di mid venture a quella di espansione, comprese selezionate società quotate in borsa e selezionate società con opportunità speciali che necessitano di capitale aggiuntivo per finanziare acquisizioni, ricapitalizzazioni e rifinanziamenti e società in fase di costituzione. L'azienda fornisce soluzioni di finanziamento del capitale di crescita per l'estensione del capitale; soluzioni di finanziamento per il management buy-out e lo spin-out aziendale; finanziamenti per l'acquisizione di aziende, attività specifiche o proprietà intellettuali; prestiti convertibili, subordinati e/o mezzanini; espansione aziendale nazionale e internazionale; finanziamento dei fornitori; accelerazione dei ricavi attraverso lo sviluppo delle vendite e del marketing ed espansione della produzione.
Mostra di più Hercules Capital, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Hercules Capital con la sua capitalizzazione di mercato? 0J4M statistiche fondamentali Capitalizzazione di mercato US$3.20b Guadagni(TTM ) US$318.41m Ricavi(TTM ) US$494.41m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 0J4M Conto economico (TTM ) Ricavi US$494.41m Costo del fatturato US$0 Profitto lordo US$494.41m Altre spese US$176.00m Guadagni US$318.41m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 1.99 Margine lordo 100.00% Margine di profitto netto 64.40% Rapporto debito/patrimonio netto 93.9%
Come si è comportato 0J4M nel lungo periodo?
Vedi performance storica e confronto Dividendi
9.6% Rendimento attuale del dividendo
79% Rapporto di remunerazione Quando è necessario acquistare 0J4M per ricevere un dividendo imminente? Hercules Capital date dei dividendi Data di stacco del dividendo Nov 13 2024 Data di pagamento dei dividendi Nov 20 2024 Giorni fino al dividendo Ex 0 days Giorni prima della data di pagamento dei dividendi 7 days
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
